Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Naringenin as a potential immunomodulator for attenuating lung abnormal inflammation in Chronic Obstructive Pulmonary Disease (COPD) via the NF-κB/NLRP3/Caspase-1 Axis.

Cytotechnology·2026
Same author

Role of Mannose-binding Lectin-2 Promoter Genetic Variants in Susceptibility to Sepsis: A Meta and Trial Sequential Analysis.

Iranian journal of allergy, asthma, and immunology·2026
Same author

Characteristics and influencing factors of bronchoalveolar lavage fluid cellular patterns in children with <i>Mycoplasma pneumoniae</i> pneumonia: a cross-sectional study.

Translational pediatrics·2026
Same author

Indole-3-carbaldehyde mitigates fibrosis progression in MASH with T2DM via the SIRT1/TGF-β/SMAD signaling pathway.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

Divergent pathogenic mechanisms of influenza A and influenza B viruses.

Archives of microbiology·2026
Same author

hERG channel blockade and additive interactions of magnolol and honokiol from Magnolia species.

Toxicology letters·2026

Related Experiment Video

Updated: Oct 7, 2025

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.7K

Photo-Triggered Delivery of siRNA and Paclitaxel into Breast Cancer Cells Using Catanionic Vesicles.

Zumra Peksaglam Seidel1, Xiaoyang Zhang1, Melanie A MacMullan1

  • 1Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, California 90089, United States.

ACS Applied Bio Materials
|January 12, 2022
PubMed
Summary

Researchers developed photoresponsive nanovesicles for targeted cancer therapy. These vesicles deliver chemotherapy drugs and siRNA, releasing them with UV light to enhance cancer cell death and reduce side effects.

Keywords:
azoTABazobenzene-based catanionic vesicleschemotherapeutic drug deliverylight triggered deliveryphotoresponsive surfactantsphotoresponsive synergistic deliverysiRNA deliverystimuli-responsive nanoparticles

More Related Videos

Preparation of Exosomes for siRNA Delivery to Cancer Cells
09:59

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

25.4K
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.6K

Related Experiment Videos

Last Updated: Oct 7, 2025

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.7K
Preparation of Exosomes for siRNA Delivery to Cancer Cells
09:59

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

25.4K
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.6K

Area of Science:

  • Biochemistry
  • Materials Science
  • Nanotechnology

Background:

  • Localized drug delivery can minimize chemotherapy's toxicity and side effects.
  • Designing nanocarriers that are both durable for delivery and degradable for payload release remains a challenge.

Purpose of the Study:

  • To utilize photoresponsive catanionic vesicles for co-delivery of Bcl-2 siRNA and paclitaxel into human breast cancer cells.
  • To achieve phototriggered release of therapeutics for enhanced cancer cell death and protein suppression.

Main Methods:

  • Formulation of catanionic vesicles from azobenzene-based cationic and anionic surfactants.
  • Characterization using dynamic light scattering, zeta potential, small-angle neutron scattering, and fluorescence spectroscopy.
  • Assessment of cellular effects via cell viability assays, flow cytometry, confocal microscopy, and Western blots for Bcl-2 protein knockdown.

Main Results:

  • Photoresponsive vesicles were successfully formulated and characterized for optimal size, charge, and concentration.
  • UV illumination triggered vesicle disassociation and release of coloaded therapeutics.
  • Enhanced cancer cell death and suppression of Bcl-2 protein expression were observed post-treatment.

Conclusions:

  • Photoresponsive catanionic vesicles offer a promising platform for localized and triggered drug delivery in cancer therapy.
  • This approach enhances therapeutic efficacy by enabling controlled release of combined therapeutic agents.
  • The study demonstrates a viable strategy for overcoming limitations of traditional chemotherapy.